30 results about "Pancreatic islet function" patented technology

The invention relates to the technical field of medical information processing, in particular to a type 2 diabetes precise typing and dynamic treatment system which comprises a clinical feature extraction module, a metabolism dynamic modeling module, a precise typing module, a treatment parameter generation module and a dynamic treatment output module. Wherein the clinical feature extraction module is used for collecting a multi-dimensional clinical data set of a patient for continuous 14 days; the metabolism dynamic modeling module is used for extracting blood glucose fluctuation characteristics and pancreas islet function compensation characteristics; the precise typing module is used for dividing metabolism-driven subtypes to which the patients belong through a clustering algorithm; the treatment parameter generation module is used for mapping a subtype-treatment rule base and outputting a matched personalized treatment parameter combination; and the dynamic treatment output module outputs a dynamic treatment scheme. According to the invention, through a dynamic treatment mechanism based on typing, linkage control of individual difference identification and real-time adjustment of the medication scheme of the type 2 diabetes patients is realized, and the accuracy and adaptability of treatment are improved.

This invention discloses the application of IKK inhibitors in the preparation of drugs to restore pancreatic islet function. IKK inhibitors can effectively improve the problem of pancreatic β-cell differentiation defects, significantly increase the number of pancreatic β-cells, enhance the insulin secretion capacity of islet cells, and specifically upregulate the expression of key functional genes of pancreatic β-cells such as INS and NKX6.1 genes, thus repairing pancreatic islet function damage. This solves the technical problem that current treatments for type 1 diabetes can only replace insulin and relieve blood sugar symptoms, but cannot fundamentally repair pancreatic islet function. IKK inhibitors can be used to prepare drugs for the treatment of type 1 diabetes, providing a new approach for the clinical treatment of type 1 diabetes and possessing extremely high clinical translational value.

The invention relates to the technical field of functional probiotic screening and application, and particularly provides a strain of lactobacillus plantarum capable of improving pancreas islet dysfunction and diabetic nephropathy and application of the lactobacillus plantarum capable of improving pancreas islet dysfunction and diabetic nephropathy. The preservation number of the plant lactobacillus is CGMCC (China General Microbiological Culture Collection Center) No.31657, and the plant lactobacillus is screened from excrement of healthy infants, has excellent acid resistance and cholate resistance, is high in oxidation resistance and reducing capacity, can effectively control the rise of fasting blood-glucose level of diabetic mice and can enhance the glucose tolerance of the diabetic mice; and the protein also has the capabilities of improving pancreas islet functions and regulating insulin resistance and insulin sensitivity. The strain has a wide application prospect in preparation of drugs for relieving or treating pancreas islet dysfunction and diabetic nephropathy.

The invention relates to the technical field of biology, in particular to application of SAFit2 in preparation of a reagent for improving pancreas islet dysfunction. The invention discovers that SAFit2 has a remarkable improvement effect on insulin secretion dysfunction in a high-glucose and high-fat induced islet injury model. Experiments show that in a high glucose (33 mM) combined palmitic acid (500 [mu] M) injury model, the SAFit2 can significantly improve the insulin secretion function of the pancreas islet. Specifically, the SAFit2 is pretreated, the glucose stimulated insulin secretion (GSIS) index of the pancreas islet and the intracellular insulin content are remarkably increased, insulin secretion under high glucose stimulation is promoted, and the SAFit2 is proved to have the effect of promoting the insulin secretion function of the pancreas islet beta cells.

The invention relates to a traditional Chinese medicine composition for treating prediabetes and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The composition is prepared from the following raw material medicines: 10 to 20 parts of rhizoma coptidis, 20 to 30 parts of radix astragali seu hedysari, 20 to 30 parts of rhizoma dioscoreae, 12 to 30 parts of rhizoma atractylodis, 10 to 20 parts of herba eupatorii, 15 to 30 parts of roasted rhizoma atractylodis macrocephalae, 15 to 20 parts of poria cocos and 10 to 20 parts of radix ophiopogonis. The traditional Chinese medicine composition disclosed by the invention is prepared according to the traditional Chinese medicine theory of replenishing qi to invigorate the spleen, clearing heat and drying dampness, nourishing yin and promoting the secretion of saliva or body fluid, and aims at regulating glycometabolism, improving the pancreas islet function and controlling abnormal blood glucose; the preparation method comprises the steps of crushing, mixing, wet granulation, drying and the like, and the stability and the curative effect consistency of the granules are ensured. The traditional Chinese medicine composition has the advantages of multiple targets, low side effect, high compliance and the like by systematically optimizing the formula and standardizing the preparation process, is suitable for intervention treatment of the early stage of diabetes, and has good clinical value and industrialization prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of dronedarone hydrochloride in preparation of anti-obesity and anti-diabetes medicines. According to the invention, ob / ob mouse and db / db mouse models are used, and experiments find that dronedarone hydrochloride can significantly reduce the weight of obese and diabetic mice, inhibit appetite, reduce fat content and liver weight, improve pancreas islet function, reduce serum glucose level, and effectively alleviate obesity and diabetes diseases. The potential application of dronedarone hydrochloride in treatment of obesity and type II diabetes provides new possibility for clinical treatment, and dronedarone hydrochloride is expected to become a new medicine for treating obesity and type II diabetes.

The invention discloses a blood sugar reducing composition containing rumex hanus as well as a preparation method and application thereof, and the blood sugar reducing composition containing rumex hanus is prepared from the following raw materials in parts by weight: 19 to 21 parts of rumex hanus extract, 29 to 31 parts of white kidney bean extract, 8 to 10 parts of arabinose and 30.4 to 49.6 parts of auxiliary components. The invention relates to a preparation method and application of a hypoglycemic composition containing rumex hanus. According to the hypoglycemic composition based on the theory of homology of medicine and food provided by the invention, various plant extracts are scientifically proportioned to play a synergistic effect, so that a multi-way hypoglycemic effect of inhibiting exogenous sugar absorption, regulating endogenous sugar metabolism, improving pancreas islet function and resisting oxidative damage is realized; the composition has the advantages of high safety, small side effect, lasting effect and the like.

The invention discloses a traditional Chinese medicine ointment for improving pancreas islet function and a preparation method and application thereof. The traditional Chinese medicine ointment is prepared from ginseng, astragalus membranaceus, radix ophiopogonis, salvia miltiorrhiza, corn stigma, radix polygonati officinalis, radices trichosanthis, dandelion root, Chinese yam, poria cocos, radix puerariae, purslane, potentilla discolor, cyclocarya paliurus, folium mori, liquorice, momordica grosvenori, radix rehmanniae recen, coptis chinensis, chrysanthemum, honeysuckle, buckwheat, rhizoma anemarrhenae, cinnamon, bitter gourd, gynostemma pentaphyllum, cortex lycii radicis, rhizoma phragmitis and the like according to a specific weight part ratio. The invention further provides a preparation method of the traditional Chinese medicine ointment. The preparation method comprises the steps of soaking in water, decocting and extracting, filtering and concentrating, ointment collecting and the like. The traditional Chinese medicine ointment can remarkably reduce fasting blood glucose and postprandial blood glucose of diabetic model mice and improve abnormal glucose tolerance, and has a protection effect on pancreas islet tissues. The traditional Chinese medicine ointment can be used for preparing health care products for assisting in reducing blood sugar or pharmaceutical compositions for preventing and assisting in treating type 2 diabetes mellitus, and has the advantages of reasonable formula, exact curative effect, stable preparation process and the like.

The application provides application of PVRIG as a target point in preparation of a type 1 diabetes diagnosis and disease progression prediction product. Specifically, PVRIG has different expressions on the surfaces of NK cells, CD16 positive NK cells and CD16 negative NK cells in honeymoon patients and non-honeymoon patients of type 1 diabetes, and PVRIG has different expressions on the surfaces of NK cells, CD16 positive NK cells and CD16 negative NK cells in patients with faster islet function failure and patients with slower islet function failure of type 1 diabetes, so that PVRIG is closely related to type 1 diabetes, can be used as a new target point of type 1 diabetes, and provides a new way for diagnosis and disease progression prediction of type 1 diabetes.

The invention discloses a pancreatic beta cell precursor cell transplantation chip based on human-derived iPSC (induced pluripotent stem cell) as well as a preparation method and application of the pancreatic beta cell precursor cell transplantation chip. The chip is composed of beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) and a porous degradable bracket (PCL / hyaluronic acid composite material), wherein the beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) are obtained by performing four-stage induction on autologous iPSC. The preparation method comprises the steps of autologous iPSC acquisition, beta cell precursor cell induction, three-dimensional bracket preparation and chip assembly. After the chip is implanted into the pancreas of a patient through minimally invasive surgery, precursor cells are differentiated into mature beta cells in vivo, insulin is secreted, the stent is gradually degraded, the pancreas islet function can be fundamentally improved, and the chip is used for treating type I and type II diabetes mellitus. The invention avoids immunological rejection, improves cell survival and functional stability, and has significant clinical transformation value.

This invention discloses a digital assessment method and system for human pancreatic islet function based on AI algorithms, belonging to the field of artificial intelligence medical assessment technology. The method includes: collecting and preprocessing multimodal physiological data; extracting multi-source features to generate low-dimensional input vectors; performing dynamic weighted fusion based on a spatiotemporal attention mechanism; constructing a neural differential equation model incorporating the β-cell biphasic secretion mechanism to output pancreatic islet function assessment indicators; and generating dynamic assessment reports through visualization and early warning modules. This invention can improve the accuracy of modeling pancreatic islet function under complex behavioral disturbances, achieve individualized quantitative assessment of functional decline trends and sensitivity scores, enhance the reference value of clinical staging and model interpretability, and solve the technical problems of low fusion accuracy, poor dynamism, and lack of physiological constraints in existing methods.

The present invention provides a reagent for detecting the expression level of PVRIG on T cells in the preparation of products for diagnosing type 1 diabetes and predicting disease progression. Specifically, it relates to the expression of PVRIG on CD8 T cells in patients with type 1 diabetes in the honeymoon period and non-honeymoon period. + T cells, CCR7 ‑ CD8 + T cells and CCR7 + CD8 + There are differences in the expression of CD8 T cells and PVRIG in patients with type 1 diabetes who have rapid islet failure and those who have slow islet failure. + T cells, CCR7 ‑ CD8 + T cells and CCR7 + CD8 + There is differential expression on the surface of T cells, which indicates that PVRIG is closely related to type 1 diabetes and can serve as a new target for type 1 diabetes, providing a new approach for the diagnosis of type 1 diabetes and the prediction of disease progression.

The invention belongs to the technical field of Chinese herbal medicines, and particularly relates to a traditional Chinese medicine herbal composition for preventing and treating diabetic complications and a preparation method thereof. The traditional Chinese medicine herbal composition is prepared from folium mori, radix astragali, radix rehmanniae, radix polygonati officinalis, radix ophiopogonis, rhizoma dioscoreae, poria cocos, radix puerariae, opuntia ficus-indica, inulin, rumex hanus, American ginseng and rhizoma curcumae longae. The traditional Chinese medicinal materials are combined to clean sugar scale micro-crystals in blood vessel microcirculation, improve the functions of liver and pancreas islet, regulate the blood sugar level and enhance the anti-oxidation and self-healing capability of a body, so that the blood sugar is stabilized; the occurrence of diabetic complications such as fundus retinopathy, neuropathy, hypertension, cerebral infarction, myocardial infarction, uremia and gangrene is prevented and controlled. Besides, the traditional Chinese medicine composition is a pure herbal traditional Chinese medicine formula, is high in safety and exact in curative effect, and has a wide application prospect in the field of prevention and treatment of diabetic complications.

The invention belongs to the technical field of medicines, and relates to a preparation method of a traditional Chinese medicine extract, in particular to a rhizoma panacis majoris overground part extract and application thereof in a medicine for repairing pancreas islet functions. Effective blood sugar reduction and pancreas islet repair functions play a key role in regulation of human blood fat, blood pressure and blood sugar homeostasis. However, in existing medical practices, improvement of the blood glucose state is often regarded as an isolated index and is not sufficiently associated with the overall metabolic disorder. Therefore, when a patient sees a doctor due to abnormal blood glucose and related complications thereof, a diabetes management method is always used in a treatment strategy, only the dose of the medicine for controlling and reducing blood glucose is adjusted, and the repair of the physical state and the pancreatic function is neglected. One purpose of the present invention is to provide an extract comprising a rhizoma panacis majoris leaf extract. The extract can improve the pancreas islet function of a human body with a medical purpose or a health-care purpose on the basis of reducing the injury to the liver and kidney of the human body.

The invention discloses an application of methyl cellulose in suspension culture of pancreatic cell masses. The invention also provides a method for suspension culture of a pancreatic cell mass, a pancreatic cell mass culture produced by the method, and a pharmaceutical composition and application of the pancreatic cell mass culture. The method provided by the invention comprises the step of carrying out suspension culture on pancreatic cell clusters in a culture medium containing methylcellulose, the number of the cell clusters cultured and harvested by the method is more, the average diameter of the cell clusters is better controlled, and the expression proportion of related markers is higher; the method has a good application prospect in preparation of regenerated pancreas islet tissues and treatment of diseases or symptoms related to pancreas islet function impairment.

The application discloses application of a reagent for detecting NETs in evaluation of early prognosis after islet transplantation. The application verifies that early NETs increase after islet transplantation is related to transplantation prognosis and islet function through experiments. The application can stratify and evaluate early prognosis after islet transplantation in an extremely early stage after islet transplantation, and the earliest time is 2 hours after islet transplantation, and early prognosis after islet transplantation is judged based on changes in detection levels. The application discloses an important role of NETs in islet transplantation prognosis, provides a simple, reliable and quantifiable evaluation method, and has important clinical significance and social and economic benefits for improving the management level of islet transplantation patients, reducing early islet loss after islet transplantation and saving medical resources.

A method to enhance beta-islet function and survival for treatments of diabetes by targeting PRKAR2B, and a method of preparing genetically modified human pluripotent stem cell (hPSC) in vitro, comprising providing hPSCs, with said modification comprising reducing or eliminating the expression or function of the gene products of the PRKAR2B gene in said hPSCs to be capable of differentiating in vitro to give rise to beta islets with enhanced function in glucose-stimulated insulin secretion and cell survival,are provided.

This disclosure describes a complex, its preparation method, and its application. The complex is a mesenchymal stem cell exosome modified with a nucleic acid aptamer that can specifically recognize beta cells. Applications include using the complex in the preparation of a reagent for improving pancreatic islet function in diabetic patients and in the preparation of a reagent for inhibiting ferroptosis of beta cells. According to this disclosure, a complex for improving pancreatic islet function in diabetic patients, its preparation method, and its application can be provided.

The application relates to the technical field of stem cell engineering and regenerative medicine, and specifically discloses a stem cell treatment method for treating type 2 diabetes. The method comprises the following steps: S1, extracting placenta-derived mesenchymal stem cells; S2, performing multi-gene modification on the mesenchymal stem cells to obtain gene-modified mesenchymal stem cells; S3, pretreating the gene-modified mesenchymal stem cells with a culture medium; S4, extracting microvesicles from the mesenchymal stem cells; S5, mixing the microvesicles, baicalin, L-arginine and vitamin D in a buffer to form a composite preparation; S6, introducing the composite preparation into a patient's body through abdominal cavity intervention; and S7, performing synergistic treatment by combining oral administration of an SGLT2 inhibitor after infusion, and regularly monitoring islet function indexes. The stem cell treatment method can be used for treating type 2 diabetes, and has the advantages of being targeted to improve the islet microenvironment, promoting the recovery of beta cell function and being durable in action.

The invention discloses an application of GPR110 as a therapeutic target of type 2 diabetes mellitus. The application discovers that the GPR110 gene is used as a therapeutic target of type 2 diabetes for the first time, and provides application of adenovirus-mediated GPR110 gene overexpression in preparation of drugs for treating type 2 diabetes. In an adult type 2 diabetes mouse model db / db, through caudal vein injection of adenovirus-mediated GPR110 overexpression, it is found that the type 2 diabetes related symptoms are significantly improved. The blood glucose level and the fasting blood glucose level are obviously reduced, and an insulin tolerance test (ITT) result shows that the insulin sensitivity is obviously improved. In addition, a decrease in serum insulin level prompts a reduction in pancreatic islet function burden. The results show that the adenovirus-mediated GPR110 overexpression can effectively improve the metabolic disorder of mice with type 2 diabetes mellitus, and a new intervention method and means are provided for the treatment of the type 2 diabetes mellitus.

The invention relates to the technical field of traditional Chinese medicine, and provides a pharmaceutical composition for regulating intestinal microecological balance and reducing blood sugar, a preparation and application, and the pharmaceutical composition comprises a traditional Chinese medicine effective component composition and a probiotic composition, the traditional Chinese medicine effective component composition comprises balsam pear glycoside, purslane phenolic acid, mulberry leaf alkaloid, corn stigma flavone, buckwheat flavone, moringa oleifera leaf flavone, sophora flower flavone, pollen pini flavone, golden camellia flavone, spirulina platensis phycocyanin, opuntia ficus-indica fruit polyphenol, rhizoma tupistrae chinensis total saponin, valeriana jatamansi volatile oil, cucurbit seven sesquiterpenoids and pholidota nameko unsaturated fatty acid; the probiotic composition comprises lactobacillus gasseri, lactobacillus paracasei, lactobacillus plantarum, lactobacillus bulgaricus and clostridium sporogenes; the pharmaceutical preparation comprises the pharmaceutical composition and auxiliary materials. The invention also discloses application of the pharmaceutical composition in preparation of hypoglycemic drugs. The composition can regulate intestinal micro-ecological balance and improve intestinal health and pancreas islet functions, thereby being beneficial to reducing blood sugar.

The invention discloses a GLP1 fusion protein with pancreas islet targeting, an exosome modified by the GLP1 fusion protein as well as a preparation method and application of the GLP1 fusion protein. The structure of the fusion protein is TP-linker-Lamp2b-linker-GLP1, the amino acid sequence of the pancreas islet targeting polypeptide TP is CPKTRRVY, and the pancreas islet targeting polypeptide TP can be specifically combined with pancreas islet beta cells; the amino acid sequence of the Linker is GSGSGSGSGS, so that the immunogenicity can be reduced, and the structural shielding can be avoided; the amino acid sequence of Lamp2b is as shown in SEQ ID NO.1, and exosome membrane anchoring can be realized; the amino acid sequence of the GLP1 mutant is HGEGTFPSDVSYLEGQAAKEFI AWLVKGR, and the half-life period of the GLP1 mutant is remarkably prolonged through A2G / T7P mutation. The invention also provides a preparation method of the fusion protein modified exosome. The preparation method comprises the steps of lentiviral vector construction, hUC-MSCs transduction and exosome extraction. In-vitro and in-vivo experiments prove that the modified exosome can target pancreas islet beta cells, efficiently exert the hypoglycemic effect of the GLP1 and remarkably improve the pancreas islet function, and a novel strategy which is high in targeting property, long-acting and efficient in delivery is provided for diabetes treatment.

The invention provides a composition and a medicine for treating type 2 diabetes mellitus as well as a preparation method and application of the composition and the medicine, and belongs to the technical field of traditional Chinese medicine compositions. The composition is prepared from the following raw materials in parts by weight: 3 to 10 parts of radix puerariae, 2 to 8 parts of rhizoma polygonati, 1 to 3 parts of poria cocos and 1 to 2.5 parts of oyster. In the invention, the kudzuvine root exerts the effects of relieving exterior syndrome, abating fever, raising yang and stopping diarrhea, the rhizoma polygonati exerts the effects of tonifying qi, tonifying kidney, strengthening spleen and moistening lung, the poria cocos has the effects of reducing blood sugar and fat, and the oyster has the effects of nourishing yin, suppressing yang, calming liver and inducing astringency. The composition disclosed by the invention not only can reduce the blood glucose level of a patient suffering from the type 2 diabetes mellitus and control complications, but also can recover normal pancreas islet functions, get rid of dependence on western medicines and insulin and realize reversion of the type 2 diabetes mellitus.

The invention relates to the field of food health-care products, in particular to a composition with a sugar control effect, a preparation method of the composition and application of the composition to the food health-care products. Comprising the following components in parts by weight: 5-15 parts of a rhodiola rosea extract, 15-25 parts of prebiotics, 10-20 parts of a mulberry leaf extract, 20-40 parts of Chinese yam powder, 3-8 parts of vitamin B family, 1-5 parts of lipoic acid, 5-15 parts of anthocyanin and 5-15 parts of an adhesive. Through synergism of multiple components of the rhodiola rosea extract, the prebiotics, the mulberry leaf extract, the Chinese yam powder, the vitamin B family, the lipoic acid and the anthocyanin, natural plant extracts are used as main materials, and necessary synthetic nutrients are used as auxiliary materials, so that auxiliary control of blood sugar from three dimensions of inhibiting sugar absorption, regulating metabolism and protecting pancreas islet functions can be realized, and the effect of preventing and treating pancreas islet is achieved. In addition, by reducing oxidative stress and release of inflammatory factors, nerves and blood vessels can be effectively protected, and complications of diabetes mellitus can be prevented or delayed.

The invention specifically discloses a pancreas islet-like organ simulating an in-vivo pancreas and a construction method and application thereof, and relates to the technical field of organoid culture. According to the pancreas islet organ construction method, the technical cost is greatly reduced, and the obtained pancreas islet is high in functionality, small in intra-group difference, high in repeatability, small in batch difference and simple to operate. The method not only can be applied to disease mechanism and mechanism research in the industry and large-scale compound screening application, but also can be combined with a reprogramming technology to be applied to personalized precise medical treatment of patients.

The present application relates to the technical field of traditional Chinese medicine, and specifically discloses a traditional Chinese medicine composition for treating diabetes and a preparation method thereof, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: Morinda officinalis, Cistanche deserticola, Cynomorium songaricum, Rehmannia root, Cornus officinalis, Chinese yam, dried tangerine peel, Poria peel, ginger peel, Morus alba bark, Citrus grandis peel, soy lecithin, and unsaturated fatty acids; the present application innovatively adds soy lecithin and unsaturated fatty acids to the traditional Chinese medicine compound, mixes and emulsifies the two with volatile oil extracted from the traditional Chinese medicine formula, and then mixes them with a concentrated paste extracted from the traditional Chinese medicine components to prepare the desired traditional Chinese medicine composition; the active ingredients of the obtained traditional Chinese medicine composition have good stability and high absorption and utilization rate, and can significantly lower blood sugar, reduce insulin resistance, increase insulin sensitivity, promote insulin secretion, improve pancreatic islet function, and regulate the immune system, thereby achieving the purpose of treating diabetes and reducing complications.

The invention discloses a method for treating diabetes mellitus based on traditional Chinese medicine acupoint injection viscera awakening therapy, and relates to the technical field of traditional Chinese medicine. 3ml of medicine is injected into each acupoint of 0.9 N. S, and the amount of the medicine is reduced to 1.5-2ml for children; 2, one time every two days, ten times as a course of treatment, a second course of treatment is injected every 7-10 days, three courses of treatment are continuously used, in the step 1, I can reduce the dosage of insulin, II can also reduce the amount of hypoglycemic drugs, the amount of hypoglycemic drugs can be reduced in the second course of treatment for patients with general curative effects, and in the step 2, 20% of patients with three courses of treatment can be stopped. And the acupoint target injection therapy is adopted to dredge the channels and collaterals to viscera and reach the stomach, the liver, the pancreas and the spleen, so that the balance of yin and yang of the viscera is recovered, the pancreas islet function is gradually recovered, and finally the function of the viscera is recovered.

The present invention belongs to the field of biomedicine and mainly relates to the use of the growth hormone-releasing hormone receptor agonist MR-409 in the preparation of non-alcoholic fatty liver disease (NAFLD) drugs. Currently, there are no targeted drugs for the treatment of NAFLD, and lipid-lowering drugs are usually used in combination with liver-protecting drugs. MR-409 is a new type of GHRHR-A. GHRHR is widely expressed in the liver and pancreas, and literature reports that GHRHR-A has the effects of improving islet function, promoting the survival of transplanted islets, and alleviating diabetic eye complications. In the present invention, the study found that MR409 can improve the imaging, serum enzymology, serum metabolism, and histological indicators of non-alcoholic fatty liver disease in diabetic mice, and is expected to become a therapeutic drug for non-alcoholic fatty liver disease. The present invention provides a new use of MR-409 for the treatment of non-alcoholic fatty liver disease, provides a new strategy for the treatment of non-alcoholic fatty liver disease, has important clinical therapeutic significance, and provides a scientific basis for its future development into a drug for the treatment of non-alcoholic fatty liver disease.

The invention belongs to the technical field of medicines, and relates to a preparation method of a traditional Chinese medicine extract, in particular to a rhizoma panacis majoris underground part extract and application thereof in a medicine for repairing pancreas islet functions. The promotion of blood sugar reduction and pancreas islet function recovery is crucial for steady-state repair of blood fat, blood pressure and blood sugar of human bodies. In the prior art, the relation between the hyperglycemia state (as a single expression of the blood sugar problem) and the pancreas islet function repairing is often neglected, and the hyperglycemia state is not related to the overall metabolic disorder. This means that the current treatment strategy may not fully consider the unique pathophysiological basis of abnormal blood glucose and related complications thereof, the exogenous intervention is emphasized to replace the self function of the pancreas islet, and the maintenance and repair of the pancreas islet are neglected, resulting in that the treatment effect may not be ideal. One purpose of the present invention is to provide an extract of the underground part of rhizoma panacis majoris. The extract can improve the pancreas islet function of a human body with a medical purpose or a health-care purpose on the basis of reducing the injury to the liver and kidney of the human body.

The invention relates to a kit and a system for detecting pancreatic islet function of a subject. The kit comprises a plurality of small chambers for containing different concentrations of an HCAR2 receptor activator or an HCAR3 receptor activator or an ester aqueous solution thereof. The kit provided by the invention can be used for effectively detecting the pancreatic islet function of a subject by evaluating the sensitivity degree of the subject to the HDAR2 receptor activator or the HDAR3 receptor activator or the ester thereof. The system disclosed by the invention can be used for quickly obtaining a detection result through several simple steps of operation in a short time, realizes multi-scene real-time detection in wards, physical examination centers, homes and the like, and is an objective, convenient and effective biological detection means for detecting the pancreas islet function of a subject.